Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

Yang, Hong; Liu, Hui; Chen, Yuping; Zhu, Chengchu; Fang, Wentao; Yu, Zhentao; Mao, Weimin; Xiang, Jiaqing; Han, Yongtao; Chen, Zhijian; Yang, Haihua; Wang, Jiaming; Pang, Qingsong; Zheng, Xiao; Yang, Huanjun; Li, Tao; Lordick, Florian; Benoît D’Journo, Xavier; J. Cerfolio, Robert; J. Korst, Robert; Novoa, Nuria; J. Swanson, Scott; Brunelli, Alessandro; Ismail, Mahmoud; C. Fernando, Hiran; Zhang, Xu; Li, Qun; Wang, Geng; Chen, Baofu; Mao, Teng; Kong, Min; Guo, Xufeng; Lin, Ting; Liu, Mengzhong; Fu, Jianhua; behalf of the AME Thoracic Surgery Collaborative Group, on

doi:10.1200/jco.2018.79.1483

Public

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

Published in Journal of Clinical Oncology • Aug 8, 2018

Authors:

Hong Yang

Hui Liu

Yuping Chen

Abstract

Purpose The efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. In this trial, we compared the survival and safety of NCRT plus surgery with surgery alone in patients with locally advanced ESCC. Patients ...

Subject

Medicine

Hazard ratio

Surgery

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!